Pharmacology and Therapeutics, School of Medicine, Galway Neuroscience Centre, University of Galway, Ireland.
Physiology, School of Medicine, Regenerative Medicine Institute, University of Galway, Ireland.
Pharmacol Res. 2024 Nov;209:107436. doi: 10.1016/j.phrs.2024.107436. Epub 2024 Oct 4.
Alzheimer's disease is characterized by the aggregation of β-amyloid, a pathological feature believed to drive the neuronal loss and cognitive decline commonly seen in the disease. Given the growing prevalence of this progressive neurodegenerative disease, understanding the exact mechanisms underlying this process has become a top priority. Microelectrode arrays are commonly used for chronic, non-invasive recording of both spontaneous and evoked neuronal activity from diverse in vitro disease models and to evaluate therapeutic or toxic compounds. To date, microelectrode arrays have been used to investigate β-amyloids' toxic effects, β-amyloids role in specific pathological features and to assess pharmacological approaches to treat Alzheimer's disease. The versatility of microelectrode arrays means these studies use a variety of methods and investigate different disease models and brain regions. This review provides an overview of these studies, highlighting their disparities and presenting the status of the current literature. Despite methodological differences, the current literature indicates that β-amyloid has an inhibitory effect on synaptic plasticity and induces network connectivity disruptions. β-amyloid's effect on spontaneous neuronal activity appears more complex. Overall, the literature corroborates the theory that β-amyloid induces neurotoxicity, having a progressive deleterious effect on neuronal signaling and plasticity. These studies also confirm that microelectrode arrays are valuable tools for investigating β-amyloid pathology from a functional perspective, helping to bridge the gap between cellular and network pathology and disease symptoms. The use of microelectrode arrays provides a functional insight into Alzheimer's disease pathology which will aid in the development of novel therapeutic interventions.
阿尔茨海默病的特征是β-淀粉样蛋白的聚集,这种病理特征被认为是导致疾病中常见的神经元丧失和认知能力下降的原因。鉴于这种进行性神经退行性疾病的患病率不断上升,了解这一过程的确切机制已成为当务之急。微电极阵列常用于慢性、非侵入性记录来自不同体外疾病模型的自发和诱发神经元活动,并评估治疗或毒性化合物。迄今为止,微电极阵列已被用于研究β-淀粉样蛋白的毒性作用、β-淀粉样蛋白在特定病理特征中的作用以及评估治疗阿尔茨海默病的药物方法。微电极阵列的多功能性意味着这些研究使用各种方法,研究不同的疾病模型和大脑区域。这篇综述概述了这些研究,强调了它们的差异,并介绍了当前文献的状况。尽管存在方法上的差异,但目前的文献表明β-淀粉样蛋白对突触可塑性具有抑制作用,并诱导网络连接中断。β-淀粉样蛋白对自发神经元活动的影响似乎更为复杂。总的来说,文献证实了β-淀粉样蛋白诱导神经毒性的理论,对神经元信号和可塑性产生渐进性的有害影响。这些研究还证实,微电极阵列是从功能角度研究β-淀粉样蛋白病理学的有价值的工具,有助于弥合细胞和网络病理学与疾病症状之间的差距。微电极阵列的使用为阿尔茨海默病病理学提供了功能上的深入了解,有助于开发新的治疗干预措施。